Header Logo

Connection

Douglas Golenbock to Nitric Oxide Synthase Type II

This is a "connection" page, showing publications Douglas Golenbock has written about Nitric Oxide Synthase Type II.
  1. Heneka MT, Kummer MP, Stutz A, Delekate A, Schwartz S, Vieira-Saecker A, Griep A, Axt D, Remus A, Tzeng TC, Gelpi E, Halle A, Korte M, Latz E, Golenbock DT. NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature. 2013 Jan 31; 493(7434):674-8.
    View in: PubMed
    Score: 0.102
  2. Deshmukh SD, M?ller S, Hese K, Rauch KS, Wennekamp J, Takeuchi O, Akira S, Golenbock DT, Henneke P. NO is a macrophage autonomous modifier of the cytokine response to streptococcal single-stranded RNA. J Immunol. 2012 Jan 15; 188(2):774-80.
    View in: PubMed
    Score: 0.024
  3. Wang Q, McLoughlin RM, Cobb BA, Charrel-Dennis M, Zaleski KJ, Golenbock D, Tzianabos AO, Kasper DL. A bacterial carbohydrate links innate and adaptive responses through Toll-like receptor 2. J Exp Med. 2006 Dec 25; 203(13):2853-63.
    View in: PubMed
    Score: 0.017
  4. Means TK, Jones BW, Schromm AB, Shurtleff BA, Smith JA, Keane J, Golenbock DT, Vogel SN, Fenton MJ. Differential effects of a Toll-like receptor antagonist on Mycobacterium tuberculosis-induced macrophage responses. J Immunol. 2001 Mar 15; 166(6):4074-82.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.